Monthly Archives: January 2011

Novo nordisk – repaglinide combination patent invalid

Yesterday, The district court of Michigan ruled that OB listed 6,677,358 (exp: Jun 12, 2018) patent is invalid and unenforceable. Press release “… The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 … Continue reading

Posted in Daily interesting IP news, Patent case | Tagged , , , , | Leave a comment

Patents & CI News: 18/01/2011

1) Cipro goes digital with Patent Journal (Cipro notices); This is bit late news. Last three months electronic journals are available for download here 2) Domain Therapeutics, Merck Serono enter agreement to develop drugs for Parkinson’s disease (pharmabiz) 3) MonoSol Rx, LLC … Continue reading

Posted in Daily interesting IP news | Leave a comment

Patents & CI News: 17/01/2011

1) Astellas Enters into License Agreement with TOLMAR -Expansion of Territory for Eligard in Asia, Middle East, Africa and CIS (press release); Astellas has in-licensed rights of Eligard (Leuprolide acetate) 2) Aspen completes buyout of Sigma pharma business for $900 million (thepharmaletter) … Continue reading

Posted in Daily interesting IP news | Leave a comment

Dabigatran Polymorphic patent application rejected

Dabigatran is an anticoagulant thrombin inhibitor marketed by Boehringer and marketed as Pradaxa. The Dabigatran’s product patent is granted in india (370/DEL/1998 granted as 225735). It is marketed as dabigatran etexilate mesylate. This mesylate salt form of dabigatran prodrug (etexilate) is protected … Continue reading

Posted in Daily interesting IP news | Leave a comment

Abbott Vs Glenmark – damages $16 million against glenmark – Tarka

A federal jury has awarded Abbott Laboratories $16 million in a suit against Glenmark Pharmaceuticals Ltd. over a generic version of Tarka (Trandolapril and Verapamil) http://www.law360.com/ip/articles/220381 Updates Glenmark received approval in the month of May 2010 and launched at risk. … Continue reading

Posted in Patent case | Tagged , , , , | Leave a comment

CI & Patents: 15/01/2011

1) Merck, Parexel Reach Biosimilar Development Deal. 2) Sanofi-aventis Enters into Two Research & Development Collaborations with the University of California, San Francisco  “….The first  collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes … Continue reading

Posted in Daily interesting IP news, Patent case | Leave a comment

India: patent rules (amendment) draft published

Indian patent office has published draft amendment to patent rules. This draft amendment mainly includes (i) certain new rules (Rule 19A to Rule 19J) related to India as Internalnational searching authority (ISA) and fee (schedule V); (ii) Rule 9 is … Continue reading

Posted in Daily interesting IP news | 2 Comments

CI & Patent News 12/01/2011

1) Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab “…. But Novartis’s decision will see highly unusual direct competition between the two Swiss pharmaceutical groups, which are among the world’s leaders by sales….” (FT) 2) Vertex maintains … Continue reading

Posted in Daily interesting IP news, Patent case | Leave a comment

India Case: Atazanavir

A news article posted on Medicins San Frontieres (MSF) states that two key patent applications related to HIV drugs are rejected in India in pre-grant opposition. It further states that those two drugs are Atazanavir and Lopinavir and Ritonavir. Lopinavir+ritonavir … Continue reading

Posted in Daily interesting IP news, Patent case | Tagged , , , | Leave a comment

Cinacalcet: Injunction granted against Barr/Teva

Amgen today announced that district court of delaware has granted injunction preventing launch of Teva and Barr’s generic versions of cinacalcet. Teva and Barr has received tentative approval from FDA on early 2010. Teva has tentative approval for 90 MG only; … Continue reading

Posted in Patent case | Tagged | Leave a comment